Topical Sirolimus Gel Shrinks Pediatric Microcystic Lymphatic Malformations
This single-center uncontrolled study offers pediatric pharmacists early efficacy and systemic-exposure data for a standardized 0.2% topical sirolimus gel in superficial microcystic lymphatic malformations.
Sirolimus gel proves effective for pediatric lymphatic malformations.
Lymphatic malformations (LMs) in children can cause significant discomfort and disfigurement, so effective and safe treatments are important. The study found a 96% response rate with topical sirolimus gel, significant pain reduction, and decreased lesion size without notable systemic absorption. This treatment offers an effective and safe option for managing pediatric superficial microcystic LMs, with mild side effects and maintained low blood sirolimus levels. Topical sirolimus gel shows promising efficacy and safety for treating pediatric lymphatic malformations.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Xu W, Ding Y, Zhao L, Pi M, Zhang X, Xu M, Ma K
Citation:Xu W, Ding Y, Zhao L, et al. Short-Term Efficacy and Safety of Topical Sirolimus Gel in Pediatric Superficial Microcystic Lymphatic Malformations: A Single-Center Interventional Study of 30 Patients. Vascular health and risk management. 2026;22:636544. doi:10.2147/VHRM.S636544